MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

计划入组 5,000 人 · 首次发布于 2026 年 1 月 23 日

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

计划入组 2,250 人 · 首次发布于 2015 年 11 月 23 日

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

计划入组 10 人 · 首次发布于 2021 年 8 月 27 日

5-MPN

Monovalent Pneumococcal Conjugate(Pfizer)

MP4

Tuen Mun Hospital

China

MIN SUK CHAE

Australia

MSN Pharmaceuticals Inc.

United States

NCCN Updates MPN Guidelines, Prioritizes Clinical Trials and NGS

Ropeginterferon Alfa-2b Shows Promise in Hydroxyurea-Resistant Essential Thrombocythemia

Managing Young MPN Patients: Balancing Long-term Treatment Risks and Benefits